McKesson Corporation (MCK)
Official siteHEALTHCARE • MEDICAL DISTRIBUTION • NYSE
Market Cap: $127.33B
Last updated: Nov 17, 2026 at 11:06 AM ET
McKesson Corporation (MCK) Financials: Revenue, Profit and Cash Flow
McKesson reported revenue of $403.43B for the fiscal year ended Mar 31, 2026, up 12.4% from the year before. That year, net income was $5.10B with a net margin of 1.3%, operating cash flow was $6.16B and free cash flow was $5.72B. The quarter ended Sep 30, 2026 had revenue of $110.96B and net income of $1.30B.
Revenue and Margins
The operating margin was 1.5% in the fiscal year ended Mar 2026. Over the 9 years to Mar 2026, revenue grew from $198.53B, a compound annual rate of 8.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $403.43B | +12.4% | 3.6% | 1.5% | 1.3% |
| Mar 2025 | $359.05B | +16.2% | 3.7% | 1.2% | 1.0% |
| Mar 2024 | $308.95B | +11.7% | 4.2% | 1.3% | 1.0% |
| Mar 2023 | $276.71B | +4.8% | 4.5% | 1.6% | 1.3% |
| Mar 2022 | $263.97B | +10.8% | 5.0% | 0.8% | 0.5% |
| Mar 2021 | $238.23B | +3.1% | 5.1% | -2.1% | -1.8% |
| Mar 2020 | $231.05B | +7.8% | 5.2% | 1.1% | 0.5% |
| Mar 2019 | $214.32B | +2.9% | 5.5% | 0.4% | 0.1% |
| Mar 2018 | $208.36B | +4.9% | 5.4% | 0.4% | 0.1% |
| Mar 2017 | $198.53B | N/A | 5.7% | 3.6% | 2.6% |
Income Statement
In the fiscal year ended Mar 2026, net income rose 46.6% from the year before. In the quarter ended Sep 2026, net income rose 12.1% from the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $403.43B | $359.05B | $308.95B | $276.71B | $263.97B | $238.23B | $231.05B | $214.32B | $208.36B | $198.53B |
| Cost of revenue | $388.88B | $345.73B | $296.12B | $264.35B | $250.84B | $226.08B | $219.03B | $202.56B | $197.17B | $187.26B |
| Gross profit | $14.55B | $13.32B | $12.83B | $12.36B | $13.13B | $12.15B | $12.02B | $11.75B | $11.18B | $11.27B |
| Research and development | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $125.00M | $341.00M |
| Operating income | $6.21B | $4.42B | $3.91B | $4.38B | $2.04B | -$5.04B | $2.49B | $886.00M | $762.00M | $7.12B |
| Net income | $5.10B | $3.48B | $3.16B | $3.72B | $1.29B | -$4.34B | $1.12B | $255.00M | $297.00M | $5.15B |
| EBITDA | $7.18B | $5.26B | $4.68B | $5.49B | $3.06B | -$3.93B | $3.42B | $2.02B | $1.59B | $8.11B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $110.96B | $105.38B | $96.30B | $106.16B | $103.15B | $97.83B | $90.82B | $95.29B | $93.65B | $79.28B | $76.36B | $80.90B |
| Gross profit | $3.96B | $3.69B | $4.04B | $3.69B | $3.54B | $3.28B | $3.64B | $3.28B | $3.25B | $3.15B | $3.58B | $3.15B |
| Operating income | $1.60B | $1.32B | $2.15B | $1.62B | $1.41B | $1.04B | $1.59B | $1.22B | $578.00M | $1.03B | $1.22B | $642.00M |
| Net income | $1.30B | $1.03B | $1.85B | $1.25B | $1.16B | $831.00M | $1.31B | $928.00M | $287.00M | $960.00M | $830.00M | $630.00M |
Balance Sheet
As of Mar 2026, total debt of $6.53B exceeded cash and equivalents by $2.55B. Shareholder equity was negative, at -$2.17B, as total liabilities of $83.16B exceeded total assets of $82.32B.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $82.32B | $75.14B | $67.44B | $62.32B | $63.30B | $65.02B | $61.25B | $59.67B | $60.38B | $60.97B |
| Current assets | $57.21B | $55.40B | $47.97B | $44.29B | $46.23B | $45.38B | $42.22B | $38.47B | $37.14B | $36.95B |
| Cash and equivalents | $3.98B | $5.69B | $4.58B | $4.68B | $3.53B | $6.28B | $4.01B | $2.98B | $2.67B | $2.78B |
| Total liabilities | $83.16B | $76.83B | $69.04B | $63.81B | $65.09B | $63.57B | $54.54B | $49.99B | $48.87B | $48.37B |
| Short-term debt | $1.27B | $1.19B | $50.00M | $968.00M | $799.00M | $742.00M | $1.05B | $330.00M | $1.13B | $1.24B |
| Long-term debt | $5.26B | $4.46B | $5.58B | $4.63B | $5.08B | $6.41B | $6.33B | $7.26B | $6.75B | $7.30B |
| Shareholder equity | -$2.17B | -$2.07B | -$1.97B | -$1.86B | -$2.27B | -$21.00M | $5.09B | $8.09B | $9.80B | $11.10B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $92.32B | $88.33B | $82.32B | $84.19B | $84.16B | $81.31B | $75.14B | $71.08B | $72.43B | $71.67B | $67.44B | $66.51B |
| Total liabilities | $93.34B | $89.63B | $83.16B | $84.29B | $84.74B | $82.17B | $76.83B | $73.78B | $75.07B | $73.05B | $69.04B | $68.19B |
| Cash and equivalents | $6.53B | $5.16B | $3.98B | $2.96B | $4.00B | $2.42B | $5.69B | $1.13B | $2.51B | $2.30B | $4.58B | $1.98B |
| Shareholder equity | -$3.95B | -$4.24B | -$2.17B | -$1.30B | -$1.74B | -$1.97B | -$1.69B | -$3.08B | -$3.02B | -$1.75B | -$1.60B | -$2.05B |
Cash Flow
In the fiscal year ended Mar 2026, free cash flow was 92.9% of operating cash flow. Dividends and share repurchases together came to 89.7% of it.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $6.16B | $6.08B | $4.31B | $5.16B | $4.43B | $4.54B | $4.37B | $4.04B | $4.34B | $4.74B |
| Capital expenditures | $436.00M | $537.00M | $431.00M | $390.00M | $388.00M | $451.00M | $362.00M | $426.00M | $405.00M | $404.00M |
| Free cash flow | $5.72B | $5.55B | $3.88B | $4.77B | $4.05B | $4.09B | $4.01B | $3.61B | $3.94B | $4.34B |
| Dividends paid | $381.00M | $345.00M | $314.00M | $292.00M | $277.00M | $276.00M | $294.00M | $292.00M | $262.00M | $253.00M |
| Share repurchases | $4.75B | $3.15B | $3.02B | $3.64B | $4.55B | $791.00M | $1.94B | $1.64B | $1.71B | $2.31B |
| Investing cash flow | -$3.43B | -$733.00M | -$1.07B | -$542.00M | -$89.00M | -$415.00M | -$579.00M | -$1.38B | -$2.99B | -$3.27B |
| Financing cash flow | -$4.63B | -$3.96B | -$3.34B | -$4.37B | -$6.32B | -$1.69B | -$2.73B | -$2.23B | -$3.08B | -$2.07B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.07B | -$220.00M | $3.42B | $1.23B | $2.42B | -$918.00M | $7.75B | -$2.38B | $2.10B | -$1.38B | $4.15B | $254.00M |
| Capital expenditures | $65.00M | $112.00M | $111.00M | $108.00M | $106.00M | $111.00M | $169.00M | $126.00M | $136.00M | $106.00M | $188.00M | $90.00M |
| Free cash flow | $3.00B | -$332.00M | $3.31B | $1.12B | $2.31B | -$1.03B | $7.58B | -$2.51B | $1.96B | -$1.49B | $3.96B | $164.00M |
Frequently Asked Questions About MCK
What is McKesson's annual revenue?
McKesson reported revenue of $403.43B for the fiscal year ended Mar 31, 2026.
How fast is McKesson's revenue growing?
Revenue was up 12.4% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 13.4%.
Is McKesson profitable?
Yes. McKesson reported net income of $5.10B for the fiscal year ended Mar 31, 2026, with a net margin of 1.3%.
How much free cash flow does MCK generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of $6.16B minus capital expenditures of $436.00M produced free cash flow of $5.72B.
How much debt does McKesson have?
The balance sheet dated Mar 31, 2026 reported long-term debt of $5.26B, short-term debt of $1.27B and cash and equivalents of $3.98B.
MCK pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts